ATE229943T1 - Zwischenprodukte zur herstellung von 1- substituierten, 2-substituierten-1h-imidazo(4,5- c)chinolin-4-aminen - Google Patents

Zwischenprodukte zur herstellung von 1- substituierten, 2-substituierten-1h-imidazo(4,5- c)chinolin-4-aminen

Info

Publication number
ATE229943T1
ATE229943T1 AT98105754T AT98105754T ATE229943T1 AT E229943 T1 ATE229943 T1 AT E229943T1 AT 98105754 T AT98105754 T AT 98105754T AT 98105754 T AT98105754 T AT 98105754T AT E229943 T1 ATE229943 T1 AT E229943T1
Authority
AT
Austria
Prior art keywords
substituted
imidazo
amines
quinoline
production
Prior art date
Application number
AT98105754T
Other languages
English (en)
Inventor
John F Gerster
Stephen L Crooks
Kyle J Lindstrom
Original Assignee
Minnesota Mining & Mfg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minnesota Mining & Mfg filed Critical Minnesota Mining & Mfg
Application granted granted Critical
Publication of ATE229943T1 publication Critical patent/ATE229943T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Lubricants (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
AT98105754T 1991-03-01 1992-02-20 Zwischenprodukte zur herstellung von 1- substituierten, 2-substituierten-1h-imidazo(4,5- c)chinolin-4-aminen ATE229943T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66292691A 1991-03-01 1991-03-01
US68732691A 1991-04-18 1991-04-18

Publications (1)

Publication Number Publication Date
ATE229943T1 true ATE229943T1 (de) 2003-01-15

Family

ID=27098631

Family Applications (2)

Application Number Title Priority Date Filing Date
AT92906763T ATE179711T1 (de) 1991-03-01 1992-02-20 1,2-substituierte 1h-imidazo(4,5-c>chinolin-4- amine
AT98105754T ATE229943T1 (de) 1991-03-01 1992-02-20 Zwischenprodukte zur herstellung von 1- substituierten, 2-substituierten-1h-imidazo(4,5- c)chinolin-4-aminen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT92906763T ATE179711T1 (de) 1991-03-01 1992-02-20 1,2-substituierte 1h-imidazo(4,5-c>chinolin-4- amine

Country Status (18)

Country Link
EP (2) EP0872478B1 (de)
JP (1) JP2955019B2 (de)
AT (2) ATE179711T1 (de)
AU (2) AU658621B2 (de)
CA (2) CA2289219C (de)
CZ (1) CZ285050B6 (de)
DE (2) DE69229114T2 (de)
DK (2) DK0582581T3 (de)
ES (2) ES2131070T3 (de)
HU (5) HU222247B1 (de)
IE (1) IE920605A1 (de)
IL (2) IL101110A (de)
NO (1) NO303729B1 (de)
NZ (1) NZ241784A (de)
PH (1) PH31614A (de)
SG (2) SG70625A1 (de)
UA (1) UA32546C2 (de)
WO (1) WO1992015582A1 (de)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266575A (en) * 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
US5395937A (en) * 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
US5352784A (en) * 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
DK0708772T3 (da) * 1993-07-15 2000-09-18 Minnesota Mining & Mfg Imidazo[4,5,-c]pyridin-4-aminer
US5648516A (en) * 1994-07-20 1997-07-15 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5482936A (en) * 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
US6133547A (en) * 1996-09-05 2000-10-17 Medtronic, Inc. Distributed activator for a two-dimensional shape memory alloy
US5939090A (en) * 1996-12-03 1999-08-17 3M Innovative Properties Company Gel formulations for topical drug delivery
JPH10298181A (ja) * 1997-04-25 1998-11-10 Sumitomo Pharmaceut Co Ltd タイプ２ヘルパーｔ細胞選択的免疫応答抑制剤
UA74852C2 (en) * 2000-12-08 2006-02-15 3M Innovative Properties Co Urea-substituted imidazoquinoline ethers
UA74593C2 (en) * 2000-12-08 2006-01-16 3M Innovative Properties Co Substituted imidazopyridines
EP1541572A1 (de) * 2000-12-08 2005-06-15 3M Innovative Properties Company Thioether substituierte Imidazochinoline
US6664264B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
MXPA05000893A (es) * 2002-07-23 2005-09-30 Biogal Gyogyszergyar Preparacion de 1h-imidazo[4,5-c]quinolin-4-aminas a traves de compuestos intermedios 1h-imidazo [4,5-c] quinolin-4-ftalimida.
US8871782B2 (en) 2003-10-03 2014-10-28 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
AR046781A1 (es) 2003-11-25 2005-12-21 3M Innovative Properties Co Derivados de imidazoquinolinas. composiciones farmaceuticas.
EP1765348B1 (de) * 2004-06-18 2016-08-03 3M Innovative Properties Company Substituierte imidazochinoline, imidazopyridine sowie imidazonaphthyridine
US8080560B2 (en) 2004-12-17 2011-12-20 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
AU2006210392A1 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune response modifiers
JP2008530245A (ja) 2005-02-18 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 尿路病原性菌株由来の抗原
AU2006214064B2 (en) 2005-02-18 2012-04-26 J. Craig Venter Institute, Inc. Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
EP1851224A2 (de) 2005-02-23 2007-11-07 3M Innovative Properties Company Hydroxyalkyl-substituierte imidazochinoline
US8158794B2 (en) 2005-02-23 2012-04-17 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinoline compounds and methods
EP1850849A2 (de) 2005-02-23 2007-11-07 Coley Pharmaceutical Group, Inc. Verfahren zur vorzugsweisen herbeiführung der biosynthese von interferon
US7943636B2 (en) 2005-04-01 2011-05-17 3M Innovative Properties Company 1-substituted pyrazolo (3,4-C) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
WO2007052055A1 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
ES2377884T3 (es) 2005-11-04 2012-04-02 Novartis Vaccines And Diagnostics S.R.L. Vacunas contra la gripe que incluyen combinaciones de adyuvantes particulados e inmunopotenciadores
NZ594482A (en) 2005-11-04 2012-11-30 Novartis Vaccines & Diagnostic Influenza vaccines with reduced amount of oil-in-water emulsion as adjuvant
CA2628424A1 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics S.R.L. Adjuvanted influenza vaccines including cytokine-inducing agents
ES2429170T3 (es) * 2005-11-04 2013-11-13 3M Innovative Properties Company 1H-Imidazoquinolinas sustituidas con hidroxilo y alcoxilo y métodos
PL2478916T3 (pl) 2006-01-27 2020-11-16 Seqirus UK Limited Szczepionki przeciw grypie zawierające hemaglutyninę i białka macierzy
WO2007110776A1 (en) 2006-03-24 2007-10-04 Novartis Vaccines And Diagnostics Gmbh & Co Kg Storage of influenza vaccines without refrigeration
EP2019686B1 (de) 2006-03-31 2012-07-11 Novartis AG Kombinierte mukosale und parenterale immunisierung gegen hiv
DK2054431T3 (da) 2006-06-09 2012-01-02 Novartis Ag Konformere af bakterielle adhæsiner
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
CA2659733A1 (en) 2006-07-31 2008-02-07 3M Innovative Properties Company Sterilized topical compositions of 1-(2-methylpropyl)-1h-imidazo[4,5-c]quinolin-4-amine
EP2586790A3 (de) 2006-08-16 2013-08-14 Novartis AG Immunogene von uropathogenen Escherichia coli
NZ575271A (en) 2006-09-11 2011-09-30 Novartis Ag Making influenza virus vaccines without using eggs
JP2011506264A (ja) 2006-12-06 2011-03-03 ノバルティス アーゲー インフルエンザウイルスの４つの株に由来する抗原を含むワクチン
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
BRPI0811125A2 (pt) * 2007-05-08 2017-05-09 Astrazeneca Ab imidazoquinolinas com propriedades imunomoduladoras
PT2185191E (pt) 2007-06-27 2012-11-27 Novartis Ag Vacinas contra a gripe com baixo teor de aditivos
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
SI2268618T1 (sl) * 2008-03-03 2015-09-30 Novartis Ag Spojine in sestavki kot modulatorji aktivnosti TLR
JP5518041B2 (ja) 2008-03-18 2014-06-11 ノバルティス アーゲー インフルエンザウイルスワクチン抗原の調製における改良
KR101606219B1 (ko) * 2008-03-24 2016-03-24 4에스체 악티엔게젤샤프트 신규 치환된 이미다조퀴놀린
WO2010100632A2 (en) 2009-03-06 2010-09-10 Novartis Ag Chlamydia antigens
EP2419129A2 (de) 2009-04-14 2012-02-22 Novartis AG Zusammensetzungen zur immunisierung gegen staphylococcus aerus
DE102010018462A1 (de) 2009-04-27 2011-04-07 Novartis Ag Impfstoffe zum Schutz gegen Influenza
US10988511B2 (en) 2009-07-07 2021-04-27 Glaxosmithkline Biologicals Sa Conserved Escherichia bacterial IG-like domain (group 1) protein (ORF405) immunogens
EP4183412B1 (de) 2009-07-15 2024-08-14 GlaxoSmithKline Biologicals SA Rsv-f-proteinzusammensetzungen und verfahren zu ihrer herstellung
CA2768343A1 (en) 2009-07-16 2011-01-20 Novartis Ag Detoxified escherichia coli immunogens
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
WO2011084726A1 (en) * 2009-12-21 2011-07-14 3M Innovative Properties Company BIS [4-AMINO-2-(ETHOXYMETHYL)-1-(2-HYDROXY-2-METHYLPROPYL)-1H-IMIDAZO[4,5-c]QUINOLIN-5-IUM] 4-[(3-CARBOXYLATO-2-HYDROXYNAPHTHALEN-1-YL)METHYL]-3-HYDROXYNAPHTHALENE-2-CARBOXYLATE COMPOSITIONS AND METHODS
WO2011084725A1 (en) * 2009-12-21 2011-07-14 3M Innovative Properties Company 4-AMINO-2-(ETHOXYMETHYL)-1-(2-HYDROXY-2-METHYLPROPYL)-1H-IMIDAZO[4,5-c]QUINOLIN-5-IUM 1-HYDROXYNAPHTHALENE-2-CARBOXYLATE COMPOSITIONS AND METHODS
EP2519265B1 (de) 2009-12-30 2018-11-14 GlaxoSmithKline Biologicals SA An e.coli-trägerproteine konjugierte polysaccharidimmunogene
CN107029223A (zh) 2010-05-26 2017-08-11 西莱克塔生物科技公司 合成纳米载体联合疫苗
PL2575872T3 (pl) 2010-06-01 2021-02-22 Seqirus UK Limited Zatężanie antygenów szczepionkowych grypy bez liofilizacji
CA2801151A1 (en) 2010-06-01 2011-12-08 Novartis Ag Concentration of vaccine antigens with lyophilization
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
CA2808965C (en) 2010-08-20 2020-01-07 Theraject, Inc. Soluble needle arrays for delivery of influenza vaccines
EP2640190A4 (de) 2010-11-05 2016-05-11 Selecta Biosciences Inc Modifizierte nikotinische verbindungen und zugehörige verfahren
ES3018416T3 (es) 2011-01-26 2025-05-16 Glaxosmithkline Biologicals Sa Régimen de inmunización del VRS
RS56748B1 (sr) 2011-05-13 2018-03-30 Glaxosmithkline Biologicals Sa Pre-fuzioni rsv f antigeni
US8728486B2 (en) 2011-05-18 2014-05-20 University Of Kansas Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds
CN103764171B (zh) 2011-07-08 2016-08-17 诺华股份有限公司 酪氨酸连接方法
RU2636350C2 (ru) 2011-11-07 2017-11-22 Новартис Аг МОЛЕКУЛА, СОДЕРЖАЩАЯ SPR0096 и SPR2021
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
MX2015004171A (es) 2012-10-02 2015-10-22 Glaxosmithkline Biolog Sa Conjugados de sacaridos no lineales.
CN105142666A (zh) 2012-11-30 2015-12-09 葛兰素史密丝克莱恩生物有限公司 假单胞菌抗原和抗原组合
BR122021012629B1 (pt) 2013-02-01 2022-06-07 Wellstat Therapeutics Corporation Compostos de amina, composição compreendendo os referidos compostos e usos dos mesmos
EP2870974A1 (de) 2013-11-08 2015-05-13 Novartis AG Salmonella-Konjugatimpfstoffe
MX377794B (es) 2014-03-26 2025-03-10 Glaxosmithkline Biologicals Sa Antigenos estafilococicos mutantes.
ES2804101T3 (es) 2014-04-22 2021-02-03 Hoffmann La Roche Compuestos de 4-amino-imidazoquinolina
HUE042563T2 (hu) 2015-03-06 2019-07-29 Hoffmann La Roche Benzazepin-dikarboxamid vegyületek
RU2722149C1 (ru) * 2015-09-14 2020-05-27 Пфайзер Инк. Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2
WO2017046112A1 (en) 2015-09-17 2017-03-23 F. Hoffmann-La Roche Ag Sulfinylphenyl or sulfonimidoylphenyl benzazepines
WO2017202704A1 (en) 2016-05-23 2017-11-30 F. Hoffmann-La Roche Ag Benzazepine dicarboxamide compounds with tertiary amide function
EP3464274B1 (de) 2016-05-23 2020-05-27 H. Hoffnabb-La Roche Ag Benzazepindicarboxamidverbindungen mit sekundärer amidfunktion
EP3468963B1 (de) 2016-06-12 2021-10-27 F. Hoffmann-La Roche AG Dihydropyrimidinyl-benzazepincarboxamide verbindungen
TWI674261B (zh) * 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 調節劑
BR112019024177A2 (pt) * 2017-05-19 2020-06-02 Superb Wisdom Limited Derivados de resiquimode
FI3641771T3 (fi) * 2017-06-23 2026-08-11 Birdie Biopharmaceuticals Inc Farmaseuttisia koostumuksia
WO2020255038A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
BR112023011284A2 (pt) 2020-12-09 2024-02-06 Wellstat Therapeutics Corp Composto de imidazoquinolina com atividade anti-inflamatória, antifúngica, antiparasítica e antineoplásica

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1271477A (en) * 1983-11-18 1990-07-10 John F. Gerster 1h-imidazo[4,5-c]quinolin-4-amines
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
EP0385630B1 (de) * 1989-02-27 1996-11-27 Riker Laboratories, Inc. 4-Amino-1H-Imidazo(4,5-c)chinoline als antivirale Mittel

Also Published As

Publication number Publication date
IL114570A0 (en) 1995-11-27
SG70625A1 (en) 2000-02-22
HU9302457D0 (en) 1993-11-29
EP0582581B1 (de) 1999-05-06
IE920605A1 (en) 1992-09-09
IL101110A (en) 1995-12-08
CA2289219C (en) 2003-05-20
JPH06504789A (ja) 1994-06-02
CZ178893A3 (en) 1995-10-18
NO303729B1 (no) 1998-08-24
EP0872478A3 (de) 1998-11-04
HU9701089D0 (en) 1997-08-28
EP0872478B1 (de) 2002-12-18
HU9701084D0 (en) 1997-08-28
IL101110A0 (en) 1992-11-15
DE69229114T2 (de) 1999-11-04
HU222251B1 (hu) 2003-05-28
JP2955019B2 (ja) 1999-10-04
AU673309B2 (en) 1996-10-31
NO933069L (no) 1993-11-01
AU658621B2 (en) 1995-04-27
CA2104782A1 (en) 1992-09-02
CA2289219A1 (en) 1992-09-02
PH31614A (en) 1999-01-12
UA32546C2 (uk) 2001-02-15
HU222111B1 (hu) 2003-04-28
DK0582581T3 (da) 1999-11-08
WO1992015582A1 (en) 1992-09-17
AU1566992A (en) 1992-10-06
DE69232878T2 (de) 2003-11-20
DE69229114D1 (de) 1999-06-10
HU222247B1 (hu) 2003-05-28
SG46492A1 (en) 1998-02-20
IL114570A (en) 1996-10-31
IE990988A1 (en) 2000-12-13
CZ285050B6 (cs) 1999-05-12
EP0582581A1 (de) 1994-02-16
HU222250B1 (hu) 2003-05-28
EP0872478A2 (de) 1998-10-21
HU211242A9 (en) 1995-11-28
HUT67026A (en) 1995-01-30
ES2131070T3 (es) 1999-07-16
CA2104782C (en) 2001-08-07
NO933069D0 (no) 1993-08-27
DK0872478T3 (da) 2003-03-31
NZ241784A (en) 1995-06-27
AU2715795A (en) 1995-09-21
DE69232878D1 (de) 2003-01-30
HU9701083D0 (en) 1997-08-28
ES2186034T3 (es) 2003-05-01
ATE179711T1 (de) 1999-05-15

Similar Documents

Publication Publication Date Title
DE69232878D1 (de) Zwischenprodukte zur Herstellung von 1-substituierten, 2-substituierten-1H-Imidazo[4,5-c]Chinolin-4-Aminen
DK0550113T3 (da) Triazolpyrimidinderivater med fungicid virkning
ATE18048T1 (de) Carbapenem-derivate, ihre herstellung und sie enthaltende zusammensetzungen.
NO304946B1 (no) Xantinderivat samt dets anvendelse
PT920430E (pt) Derivados de purina e sua utilizacao como anticoagulantes
CZ158295A3 (en) Substituted pyrazole per se and for treating diseases, pharmaceutical compositions based thereon and intermediates for their preparation
TW221814B (de)
AU6947401A (en) Phenylpyridazine derivatives and drugs containing the same
IL88303A (en) Derivatives of 6-fluoro-7-û4-( (5-methyl-2-oxo-1,3- dioxolen-4-yl)methyl) piperazin-1-ylù-4 (1h)-oxo-1,3-thiazeto(3,2-a) quinoline-3-carboxylic acid
MY141488A (en) Hydroximic acid derivatives, processes for their preparation, and compositions comprising them
AU4149293A (en) 4-iminoquinolines, processes for their preparation, and their use
ATE203537T1 (de) Pyrazol(1,5-a)pyrimidin derivate
ATE165815T1 (de) N-phenyl-2-cyano-3-hydroxypropenamide, ihre tautomeren, ihre salze, verfahren zu ihrer herstellung, ihre anwendung als medikamente und zusammensetzungen, die sie enthalten
SG50542A1 (en) Bis (pnenyl) ethane derivatives
ATE139767T1 (de) Verfahren zur herstellung 5-pyrazolomerkaptan- derivate und dessen zwischenprodukte
DE69218718D1 (de) Pharmazeutische Zusammensetzungen die Triazole Derivate enthalten zur rektalen Verabbrechung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0872478

Country of ref document: EP

REN Ceased due to non-payment of the annual fee